PT-141
MelanocortinApproved for other indicationsBremelanotide · Vyleesi
A melanocortin agonist. Branded Vyleesi is an autoinjector. Research vials are PRN, not a daily protocol.
- Typical form
- Lyophilized vial
- Typical route
- Subcutaneous
- Display unit
- mg
- Typical vial
- 10 mg
- Half-life (approx.)
- 2.5 h
- Default in-use window
- 28 days
Labeled / commonly logged
Typical protocol
A snapshot of how this compound is logged — not a prescription. You set every number.
- Common range
- 0.5–1.75 mg
- Starting log
- 1 mg
- Cadence
- As needed
- Timing
- As needed, not a daily protocol
- Duration
- PRN with a hard weekly cap (community logs stay ≤2× / week)
Branded Vyleesi is a 1.75 mg autoinjector. Research vials are PRN. Nausea is the most commonly journaled effect.
Reconstitution note
PRN with a weekly cap in the protocol engine.
Storage
Fridge after mix.
Cautions
Nausea is commonly logged. Hard-cap frequency; do not schedule daily.
Evidence posture
Approved branded product exists for HSDD. Research vials are not that product.